Building Health, Restoring Independence

Therapeutic Pipeline

Deep Clinical-Stage Pipeline in Areas of Unmet Need

Targacept’s extensive portfolio of NNR Therapeutics represents multiple opportunities for first-in-class new treatment options for patients. 

We leverage more than two decades of scientific focus on NNRs to develop innovative, small molecule product candidates to treat nervous system diseases and disorders. NNRs are a unique class of proteins that function as a sort of “volume knob” to regulate vital biological functions.  Our NNR Therapeutics are designed to selectively modulate the activity of specific NNRs considered relevant to particular disease states, while limiting adverse side effects. We work both independently and with academic and industry collaborators to seek breakthrough treatment options for patients.

 


 

Furthering innovation for difficult-to-treat diseases and disorders

Targacept’s extensive portfolio of NNR Therapeutics
Targacept, NNR Therapeutics, neuronal nicotinic receptors, NNR, neuronal nicotinic acetylcholine receptors, nicotinic acetylcholine receptors, nAChR, nicotinic, nicotinic agonist, nicotinic antagonist, nervous system disorders, psychiatric disorders, nicotinic channel modulator, central nervous system disorders, CNS, age associated memory impairment, AAMI, mild cognitive impairment, MCI, cognition, Parkinson’s disease, L-dopa induced dyskinesia, alpha7 modulators, alpha4beta2 modulators, overactive bladder, OAB, TC-5619, TC-5214, TC-1734, AZD3480, AZD1446, TC-6987
Targacept’s extensive portfolio of NNR Therapeutics represents multiple opportunities for first-in-class new treatment options for patients